We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Investors seeking momentum may have iShares U.S. Pharmaceuticals ETF (IHE - Free Report) on radar now. The fund recently hit a new 52-week high. Shares of IHE are up approximately 29.6% from their 52-week low of $58.97/share.
But could there be more gains ahead for this ETF? Let’s take a look at the fund and the near-term outlook to get a better idea of where it might be headed.
IHE In Focus
The underlying Dow Jones U.S. Select Pharmaceuticals Index is free-float adjusted market capitalization-weighted index. It includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The fund charges 38 bps in fees.
Why The Move?
The fund IHE invests about 23.66% of its weight in Eli Lilly & Co (LLY - Free Report) . Eli Lilly stock gained on earnings and upbeat guidance. LLY shares added 9.6% over the past week. Eli Lilly’s investment spree is another positive for the fund.
The company recently said that it will invest $1.2 billion in Puerto Rico (as quoted on Economic Times). Eli Lilly recently said that it plans to build a new $3 billion manufacturing plant in the Netherlands to expand the production capacity for its experimental weight-loss pill, orforglipron, and other oral medicines (per Reuters).
More Gains Ahead?
The fund has a positive weighted alpha of 13.47. So, there is a decent outlook ahead for those who want to ride this surging ETF a shade further.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pharma ETF (IHE) Hit a 52-Week High
Investors seeking momentum may have iShares U.S. Pharmaceuticals ETF (IHE - Free Report) on radar now. The fund recently hit a new 52-week high. Shares of IHE are up approximately 29.6% from their 52-week low of $58.97/share.
But could there be more gains ahead for this ETF? Let’s take a look at the fund and the near-term outlook to get a better idea of where it might be headed.
IHE In Focus
The underlying Dow Jones U.S. Select Pharmaceuticals Index is free-float adjusted market capitalization-weighted index. It includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The fund charges 38 bps in fees.
Why The Move?
The fund IHE invests about 23.66% of its weight in Eli Lilly & Co (LLY - Free Report) . Eli Lilly stock gained on earnings and upbeat guidance. LLY shares added 9.6% over the past week. Eli Lilly’s investment spree is another positive for the fund.
The company recently said that it will invest $1.2 billion in Puerto Rico (as quoted on Economic Times). Eli Lilly recently said that it plans to build a new $3 billion manufacturing plant in the Netherlands to expand the production capacity for its experimental weight-loss pill, orforglipron, and other oral medicines (per Reuters).
More Gains Ahead?
The fund has a positive weighted alpha of 13.47. So, there is a decent outlook ahead for those who want to ride this surging ETF a shade further.